GLOW

GLOW is a product name for a blend, not a compound of its own. The blend combines three peptides: GHK-Cu, BPC-157, and TB-500. Community practice reaches for it as a skin-focused repair blend, pairing GHK-Cu, the copper peptide studied for skin remodeling and collagen ¹, with two peptides studied for soft-tissue and wound repair ². The product provides all three peptides together.

GHK-Cu

GHK-Cu is the copper(II) complex of the endogenous tripeptide glycyl-L-histidyl-L-lysine ⁴, released during tissue remodeling as a repair signal ⁵. It is studied for skin remodeling, collagen synthesis, wound healing, and antioxidant/anti-inflammatory activity ¹. The strongest human evidence is in topical aesthetic use, where small RCTs and a meta-analysis report improvements in wrinkle metrics and tissue regeneration ¹. For injectable or systemic use, human evidence is absent and dosing remains unknown ⁸.

BPC-157

BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric juice protein ⁹. It is studied for tendon, ligament, muscle, and gastrointestinal tissue repair, with extensive animal research and a few uncontrolled human pilots ¹⁰. Human studies report no adverse events but are small and uncontrolled; no randomized controlled trial has been published ¹¹. The strongest evidence is preclinical.

TB-500

TB-500 is a synthetic N-acetylated fragment of thymosin beta-4, corresponding to the actin-binding region ¹³. It is studied for soft-tissue repair, cell migration, and angiogenesis, but direct TB-500 evidence is limited largely to one rat tendon study ². Most claims are extrapolated from full-length thymosin beta-4, and no human RCTs of TB-500 exist ⁸.

GLOW's components are often described as complementary rather than proven synergistic. BPC-157 is positioned as the vascular and nitric-oxide signal for local repair, TB-500 as the migration and cytoskeletal signal, and GHK-Cu as the matrix-remodeling and collagen signal ¹⁶. The only controlled combination study found that adding BPC-157 to TB-500 produced no additive benefit over either peptide alone in a rat Achilles tendon model, suggesting overlapping downstream repair pathways ². GHK-Cu plus BPC-157 is a common community stack, but no direct combination studies are available ⁶. No published study has tested this exact combination.

The blend is reached for skin and soft-tissue repair in community practice. The table separates what component research supports at each evidence level.

GLOW is sold under one name at different ratios, and the composition reported for this blend gives no fixed milligram amounts. Because amounts are not verified on a single standardized label, the ratio varies by vendor and the label decides. A label states a composition; it does not prove it. The practical consequence is that selecting a draw for one component fixes the amount of every other component in that vial, so no component can be adjusted on its own. The interactive calculator on this page handles the math for specific labels.

Lyophilized peptides in this class are typically reconstituted with bacteriostatic water. Reconstituted vials are kept refrigerated and protected from light; many protocols call for gentle swirling rather than shaking. BPC-157 and TB-500 show matrix-dependent instability in serum, with degradation within about one week at refrigerator or room temperature, while remaining stable frozen for at least two months ²². GHK-Cu is oxidation-sensitive and can lose copper, so solutions are kept cool and used promptly ²³. The most conservative guidance across the three components is to keep reconstituted vials refrigerated and discard them within two weeks. Specific diluent volumes and dose calculations are handled by the calculator in this section.

GHK-Cu

Topical use has a long favorable safety record ¹; transient erythema and stinging are community-reported (community protocol). Injectable human safety data are absent, and the main theoretical concern is copper load or free copper from poorly characterized products ⁸. Avoid in Wilson's disease or copper-handling disorders, active malignancy, and pregnancy or breastfeeding based on absence of data and mechanism ¹⁵.

BPC-157

Small uncontrolled human pilots reported no adverse events, but total exposure is limited to fewer than 30 subjects ¹¹. Preclinical work shows endothelium-dependent vasorelaxation, suggesting theoretical hypotension with vasodilators ²⁹. Active malignancy is flagged as a relative concern because pro-angiogenic and anti-tumor evidence conflict ³⁰. Competitive athletes should not use it because of WADA status ³².

TB-500

No human safety data exist for TB-500 itself ¹⁵. Extrapolation from full-length thymosin beta-4 shows a randomized trial in myocardial infarction without peptide-attributable safety signals, but also pro-tumorigenic associations in cell and tissue studies ³⁴. Theoretical risks include pathological angiogenesis ³³, bleeding ³⁶, and injection-site reactions ³⁸.

Together

Combining three investigational peptides compounds the unknowns: there are no blend-specific safety data, and each component's unstudied long-term risks remain additive in principle. Documented product-quality problems, including contamination, misbranding, and inaccurate dosing, are the dominant real-world safety concern ³³.

GLOW's legal standing follows the most restrictive status among its components.

Because TB-500 and BPC-157 are banned or classed as unapproved substances in sport, the blend as a whole is prohibited for competitive athletes at all times. The most restrictive status controls.